Search | Clinical Trials Finder

Conditions: All Diagnosed Health Conditions, ADD/ADHD, Alopecia Areata, Ankylosing Spondylitis, Asthma, Atopic Dermatitis Eczema, Beta Thalassemia, Bipolar Disorder, Breast Cancer, Celiac Disease, Cervical Cancer, Chronic Inflammatory Demyelinating Polyneuropathy, Chronic Kidney Diseases, Chronic Obstructive Pulmonary Disease, Colon Cancer, Colorectal Cancer, Crohn's Disease, Cystic Fibrosis, Depression, Diabetes Mellitus, Duchenne Muscular Dystrophy, Endometriosis, Epilepsy, Facioscapulohumeral Muscular Dystrophy, G6PD Deficiency, General Anxiety Disorder, Hepatitis B, Hereditary Hemorrhagic Telangiectasia, HIV/AIDS, Human Papilloma Virus, Huntington's Disease, Idiopathic Thrombocytopenic Purpura, Insomnia, Kidney Cancer, Leukemia, Lung Cancer, Lupus Nephritis, Lymphoma, Melanoma, Multiple Myeloma, Multiple Sclerosis, Myositis, Myotonic Dystrophy, Ovarian Cancer, Pancreatic Cancer, Parkinson's Disease, Polycystic Kidney Diseases, Prostate Cancer, Psoriasis, Psoriatic Arthritis, Rosacea, Scleroderma, Sickle Cell Anemia, Sickle Cell Trait, Sjogren's Syndrome, Skin Cancer, Spinal Muscular Atrophy, Systemic Lupus Erythematosus, Thrombotic Thrombocytopenic Purpura, Trisomy 21, Ulcerative Colitis
Interventions: Not listed
Lead sponsor: Sanguine Biosciences; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 17,667 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2024
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Chronic Idiopathic Thrombocytopenic Purpura
Interventions: Gammaplex, intravenous immunoglobulin; Biological
Lead sponsor: Bio Products Laboratory; Other
Eligibility: 18 Years to 70 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 7
States / cities: Orange City, Florida • Chicago, Illinois • Bethesda, Maryland + 4 more

Conditions: Immune Thrombocytopenia
Interventions: Not listed
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Primary Immune Thrombocytopenia
Interventions: Rozanolixizumab, Placebo; Drug · Other
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 2
States / cities: St. Petersburg, Florida • Boston, Massachusetts

Conditions: Immune Thrombocytopenia
Interventions: Rilzabrutinib, Placebo; Drug
Lead sponsor: Principia Biopharma, a Sanofi Company; Industry
Eligibility: 10 Years and older
Enrollment: 232 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 17
States / cities: Los Angeles, California • San Francisco, California • Torrance, California + 13 more

Conditions: Autoimmune Diseases, Lupus Erythematosus, Systemic, Communicable Diseases
Interventions: Not listed
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 2,500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2028
U.S. locations: 3
States / cities: Atlanta, Georgia

Conditions: Immune Thrombocytopenic Purpura
Interventions: Fostamatinib disodium, Placebo; Drug
Lead sponsor: Rigel Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 13
States / cities: Tucson, Arizona • Los Angeles, California • Lakeland, Florida + 10 more

Conditions: Idiopathic Thrombocytopenic Purpura
Interventions: Blinded (placebo), Open Label (Avatrombopag tablets), Blinded (Avatrombopoag tablets); Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 12
States / cities: Anaheim, California • Bakersfield, California • Manchester, Connecticut + 8 more

Conditions: Idiopathic Thrombocytopenic Purpura (ITP), Immune Thrombocytopenic Purpura (ITP)
Interventions: rituximab; Drug
Lead sponsor: Neufeld, Ellis J, MD, PhD; Individual
Eligibility: 18 Months to 18 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 9
States / cities: Los Angeles, California • Palo Alto, California • San Francisco, California + 6 more

Conditions: Chronic Idiopathic Thrombocytopenic Purpura, Purpura, Thrombocytopenic, Idiopathic
Interventions: Placebo, Avatrombopag tablets; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 25
States / cities: Anaheim, California • Bakersfield, California • Concord, California + 21 more

Conditions: Immune Thrombocytopenic Purpura
Interventions: Fostamatinib Disodium; Drug
Lead sponsor: Rigel Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 9
States / cities: Tucson, Arizona • Peoria, Illinois • Lafayette, Indiana + 5 more

Conditions: Purpura, Thrombocytopenic, Idiopathic
Interventions: BIVV009 6.5 grams, BIVV009 7.5 grams; Drug
Lead sponsor: Bioverativ, a Sanofi company; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 3
States / cities: Georgetown, District of Columbia • Boston, Massachusetts • Pittsburgh, Pennsylvania

Conditions: Thrombocytopenia
Interventions: Daclizumab; Drug
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: Not listed
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Idiopathic Thrombocytopenic Purpura (ITP)
Interventions: Rituximab; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 12 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 1
States / cities: New York, New York

Conditions: Immune Thrombocytopenia
Interventions: Avatrombopag Oral Tablet; Drug
Lead sponsor: Sobi, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 20
States / cities: Tucson, Arizona • Whittier, California • Washington D.C., District of Columbia + 17 more

Conditions: Immune Thrombocytopenic Purpura (ITP)
Interventions: Mezagitamab; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 17
States / cities: Los Angeles, California • Denver, Colorado • Washington D.C., District of Columbia + 13 more

Conditions: Immune Thrombocytopenia
Interventions: PRTX-100; Drug
Lead sponsor: Protalex, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 6
States / cities: Los Angeles, California • Boston, Massachusetts • Farmington Hills, Michigan + 3 more

Conditions: Purpura, Thrombocytopaenic, Idiopathic
Interventions: eltrombopag, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 1 Year to 17 Years
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 18
States / cities: Phoenix, Arizona • Orange, California • Jacksonville, Florida + 14 more

Conditions: Purpura, Thrombocytopaenic, Idiopathic
Interventions: eltrombopag; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 2
States / cities: Gainesville, Florida • Saint Paul, Minnesota

Conditions: Immune Thrombocytopenic Purpura
Interventions: Fostamatinib Disodium, Placebo; Drug
Lead sponsor: Rigel Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Nyack, New York

Conditions: Primary Immune Thrombocytopenia
Interventions: Placebo, TAK-079; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 7
States / cities: Tucson, Arizona • Gainesville, Florida • Peoria, Illinois + 3 more

Conditions: Immune Mediated Anemia, Immune Mediated Thrombocytopenia, Chronic GVHD
Interventions: fostamatinib; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 75 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Purpura, Thrombocytopenic, Idiopathic, Autoimmune Thrombocytopenic Purpura, Purpura, Thrombocytopenic, Autoimmune
Interventions: veltuzumab; Biological
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 8
States / cities: Los Angeles, California • Riverdale, Georgia • Tucker, Georgia + 5 more

Conditions: Primary Immune Thrombocytopenia
Interventions: Rozanolixizumab, Placebo; Drug · Other
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Seattle, Washington

Search by objective public record fields.

At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions

A Study to Find How Safe and Effective GAMMAPLEX® is in Subjects With Chronic Idiopathic Thrombocytopenic Purpura (ITP)

Cognitive Dysfunction in Chronic and Persistent Immune Thrombocytopenia

A Study to Assess the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)

Study to Evaluate Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP)

Comparative Autoantibody and Immunologic Cell Marker Study

A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)

Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With ChronicITP Who Completed 28 Days of Study Treatment in Protocol 501-CL-003

Clinical Trial of Rituximab in Children and Adolescents With Chronic Idiopathic Thrombocytopenic Purpura (ITP)

Study of AKR-501 Tablets Taken Orally Once Daily for 28 Days in Patients With Chronic Idiopathic Thrombocytopenic Purpura (ITP)

Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)

A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple- Dose BIVV009 in Participants With Chronic Immune Thrombocytopenia (ITP)

Daclizumab to Treat Chronic Immune Thrombocytopenia

A Trial to Treat Patients With ITP Who Do Not Achieve a Durable Response to Rituxan Alone

Safety and Treatment Satisfaction in Adults With Chronic ITP After Switching to Avatrombopag From Eltrombopag or Romiplostim

A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia

PRTX-100-202 Open-Label, Dose Escalation Study in Adult Patients With ITP

Efficacy and Safety Study of Eltrombopag in Pediatric Patients With Thrombocytopenia From Chronic Idiopathic Thrombocytopenic Purpura (ITP)

Study Of SB-497115 in Healthy Subjects and Subjects With Mild, Moderate or Severe Renal Impairment

A Efficacy and Safety Study of Fostamatinib in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)

A Study of TAK-079 in Adults With Persistent/Chronic Primary Immune Thrombocytopenia

Using Fostamatinib to Treat Post-Hematopoietic Stem Cell Transplant Immune-mediated Cytopenias

Study of Veltuzumab (hA20) at Different Doses in Patients With ITP

A Study to Evaluate the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)